Identification of indothiazinone as a natural antiplatelet agent

Chansik Yang, Sugyeong Kwon, Se Jong Kim, Minseon Jeong, Ji-Young Park, Dongeun Park, Soon Jun Hong, Jong Wha Jung, Chungho Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cardiovascular disease, which is caused by unregulated platelet aggregation, is one of the main causes of deaths worldwide. Many studies have focused on natural products with antiplatelet effects as a safe alternative therapy to prevent the disease. In this context, an in-house chemical library was screened to find natural products capable of inhibiting the interaction between platelet integrin αIIbβ3 and fibrinogen, which is an essential step in platelet aggregation. On the basis of the screening results, indothiazinone, an alkaloid found in microbial cultures, was identified as a potential antiplatelet agent. Specifically, indothiazinone treatment significantly inhibited the binding of fibrinogen to Chinese hamster ovary cells expressing integrin αIIbβ3. It also restricted thrombin- and adenosine diphosphate-dependent spreading of human platelets on a fibrinogen matrix. More importantly, surface plasmon resonance and molecular dynamics studies suggested that indothiazinone suppressed talin-induced activation of integrin αIIbβ3 presumably by inhibiting talin-integrin interaction. In conclusion, these results suggest that indothiazinone can be used as a lead compound for the development of antiplatelet drugs with a novel mode of action.

Original languageEnglish
JournalChemical Biology and Drug Design
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Platelet Aggregation Inhibitors
Platelets
Integrins
Talin
Fibrinogen
Biological Products
Platelet Aggregation
Blood Platelets
Agglomeration
Small Molecule Libraries
Lead compounds
Surface Plasmon Resonance
Surface plasmon resonance
Molecular Dynamics Simulation
Complementary Therapies
Cricetulus
Alkaloids
Thrombin
Adenosine Diphosphate
Molecular dynamics

Keywords

  • Antiplatelet drug
  • Indothiazinone
  • Integrin αIIbβ3
  • Platelet
  • Talin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Identification of indothiazinone as a natural antiplatelet agent. / Yang, Chansik; Kwon, Sugyeong; Kim, Se Jong; Jeong, Minseon; Park, Ji-Young; Park, Dongeun; Hong, Soon Jun; Jung, Jong Wha; Kim, Chungho.

In: Chemical Biology and Drug Design, 2017.

Research output: Contribution to journalArticle

Yang, Chansik ; Kwon, Sugyeong ; Kim, Se Jong ; Jeong, Minseon ; Park, Ji-Young ; Park, Dongeun ; Hong, Soon Jun ; Jung, Jong Wha ; Kim, Chungho. / Identification of indothiazinone as a natural antiplatelet agent. In: Chemical Biology and Drug Design. 2017.
@article{7eacd98a705d47a997a93d7d890ed7f3,
title = "Identification of indothiazinone as a natural antiplatelet agent",
abstract = "Cardiovascular disease, which is caused by unregulated platelet aggregation, is one of the main causes of deaths worldwide. Many studies have focused on natural products with antiplatelet effects as a safe alternative therapy to prevent the disease. In this context, an in-house chemical library was screened to find natural products capable of inhibiting the interaction between platelet integrin αIIbβ3 and fibrinogen, which is an essential step in platelet aggregation. On the basis of the screening results, indothiazinone, an alkaloid found in microbial cultures, was identified as a potential antiplatelet agent. Specifically, indothiazinone treatment significantly inhibited the binding of fibrinogen to Chinese hamster ovary cells expressing integrin αIIbβ3. It also restricted thrombin- and adenosine diphosphate-dependent spreading of human platelets on a fibrinogen matrix. More importantly, surface plasmon resonance and molecular dynamics studies suggested that indothiazinone suppressed talin-induced activation of integrin αIIbβ3 presumably by inhibiting talin-integrin interaction. In conclusion, these results suggest that indothiazinone can be used as a lead compound for the development of antiplatelet drugs with a novel mode of action.",
keywords = "Antiplatelet drug, Indothiazinone, Integrin αIIbβ3, Platelet, Talin",
author = "Chansik Yang and Sugyeong Kwon and Kim, {Se Jong} and Minseon Jeong and Ji-Young Park and Dongeun Park and Hong, {Soon Jun} and Jung, {Jong Wha} and Chungho Kim",
year = "2017",
doi = "10.1111/cbdd.13008",
language = "English",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",

}

TY - JOUR

T1 - Identification of indothiazinone as a natural antiplatelet agent

AU - Yang, Chansik

AU - Kwon, Sugyeong

AU - Kim, Se Jong

AU - Jeong, Minseon

AU - Park, Ji-Young

AU - Park, Dongeun

AU - Hong, Soon Jun

AU - Jung, Jong Wha

AU - Kim, Chungho

PY - 2017

Y1 - 2017

N2 - Cardiovascular disease, which is caused by unregulated platelet aggregation, is one of the main causes of deaths worldwide. Many studies have focused on natural products with antiplatelet effects as a safe alternative therapy to prevent the disease. In this context, an in-house chemical library was screened to find natural products capable of inhibiting the interaction between platelet integrin αIIbβ3 and fibrinogen, which is an essential step in platelet aggregation. On the basis of the screening results, indothiazinone, an alkaloid found in microbial cultures, was identified as a potential antiplatelet agent. Specifically, indothiazinone treatment significantly inhibited the binding of fibrinogen to Chinese hamster ovary cells expressing integrin αIIbβ3. It also restricted thrombin- and adenosine diphosphate-dependent spreading of human platelets on a fibrinogen matrix. More importantly, surface plasmon resonance and molecular dynamics studies suggested that indothiazinone suppressed talin-induced activation of integrin αIIbβ3 presumably by inhibiting talin-integrin interaction. In conclusion, these results suggest that indothiazinone can be used as a lead compound for the development of antiplatelet drugs with a novel mode of action.

AB - Cardiovascular disease, which is caused by unregulated platelet aggregation, is one of the main causes of deaths worldwide. Many studies have focused on natural products with antiplatelet effects as a safe alternative therapy to prevent the disease. In this context, an in-house chemical library was screened to find natural products capable of inhibiting the interaction between platelet integrin αIIbβ3 and fibrinogen, which is an essential step in platelet aggregation. On the basis of the screening results, indothiazinone, an alkaloid found in microbial cultures, was identified as a potential antiplatelet agent. Specifically, indothiazinone treatment significantly inhibited the binding of fibrinogen to Chinese hamster ovary cells expressing integrin αIIbβ3. It also restricted thrombin- and adenosine diphosphate-dependent spreading of human platelets on a fibrinogen matrix. More importantly, surface plasmon resonance and molecular dynamics studies suggested that indothiazinone suppressed talin-induced activation of integrin αIIbβ3 presumably by inhibiting talin-integrin interaction. In conclusion, these results suggest that indothiazinone can be used as a lead compound for the development of antiplatelet drugs with a novel mode of action.

KW - Antiplatelet drug

KW - Indothiazinone

KW - Integrin αIIbβ3

KW - Platelet

KW - Talin

UR - http://www.scopus.com/inward/record.url?scp=85019871190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019871190&partnerID=8YFLogxK

U2 - 10.1111/cbdd.13008

DO - 10.1111/cbdd.13008

M3 - Article

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

ER -